超40亿元里程碑付款还没收到一半,华领医药和拜耳分手了

第一财经
22 Nov 2024

华堂宁是华领医药唯一商业化的产品,在被纳入国家医保药品目录后,华领医药股价和毛利率均大受拖累。 在华堂宁遭遇医保“灵魂砍价”一年后,华领医药(02552.HK)结束了与拜耳的商业合作。11月22日,华领医药宣布,其全资附属公司华领医药技术(上海)有限公司向拜耳医药保健有限公司发出书面通知,表示有意自2025年1月1日起,将其开发用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁(多格列艾汀,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10